Clinical Trials Browser

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03745950 2024-12-04

UTOLA

Phase 2 Completed

147 enrolled

Gynecologic

Endometrial Neoplasms

NCT03838744 2024-12-04

TOMAS2

Phase 2 Completed

130 enrolled

Sarcoma

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03378297 2024-10-30

IMPACT

Phase EARLY_PHASE1 Completed

26 enrolled

Gynecologic

Ovarian Neoplasms

NCT04456699 2024-10-29

LYNK-003

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT03205761 2024-10-18

COMETABreast

Phase 2 Completed

11 enrolled 20 charts

Breast

Advanced Breast Cancer

NCT05258747 2024-10-03

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Phase 1 Completed

70 enrolled 13 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

24 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

60 enrolled

Advanced Cancer

NCT05700669 2024-09-19

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Phase 1/2 Completed

3 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT01513174 2024-06-28

GOAL

Phase 1/2 Completed

186 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

LuPARP

CAPRI

RADIOLA

KEYLYNK-009

RADIOSARP

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

OlympiAD

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

RadioPARP

CUPISCO

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

ENDOLA

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

OVAL-1

OLAGLI

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Study to Evaluate CCS1477 in Advanced Tumours

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

L-MOCA

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

KEYLYNK-010

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

SOLI

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

BAROCCO

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

UTOLA

TOMAS2

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

IMPACT

LYNK-003

COMETABreast

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

ComPAKT

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

OPINION

GOAL